Chronic Care Costs In Managed Care
The first single-plan comparison of chronic care costs shows why cost-effective clinical approaches are critical to managed care success.
by Paul Fishman, Michael Von Korff, Paula Lozano, and Julia Hecht
ABSTRACT: This DataWatch presents estimates of the health care costs for all adults who were continuously enrolled in a large staff-model health maintenance organization (HMO) during 1992. More than one-third of these adults were diagnosed with at least one chronic condition in 1992, and costs for this population are at least twice those of the population without chronic conditions. A diagnosis of a chronic condition results in an expected increase in costs of 80 percent-300 percent, depending on age, sex, and chronic condition profile. Previous studies of the costs of chronic illness have focused on the fee-for-service sector. As managed care continues to grow, it is important that economic analyses focus on this market segment.
A lt h ou gh t he U. S. he al t h ca r e delivery system is increasingly dominated by managed care, information about health care services delivery and cost is still largely based on fee-for-service experience. Economic data based on current managed care experience are needed to inform decisions about health care services delivery and financing. Such data are particularly important for understanding the costs of providing health care services to persons with chronic medical conditions.
In the 1970s and 1980s, managed care was a relatively small part of the U.S. health care delivery system, and the fee-for-service sector was better able to provide the data necessary for cost-of-illness studies. Managed care now provides health services to a large segment of the U.S. population, and group-and staff-model health maintenance organizations (HMOs) in particular are now better equipped to provide the same level of detail on ambulatory diagnoses and the resources devoted to individual patients.
This DataWatch is the first comparative analysis of the direct costs of common chronic conditions among adults based exclusively on data from managed care. Simultaneous analysis of the cost of multiple diseases is necessary to understand the relative economic burden of specific chronic conditions. Previous research has focused on either one or a small number of conditions, so the relative economic impact of different conditions has not been assessed. The lack of studies comparing the costs of multiple chronic illnesses or conditions is attributable in large part to the lack of financially comparable and diagnostically consistent data. Our estimates are unique because we used data from a single large managed care plan, thus satisfying these two requirements.
Data Sources And Methods
This DataWatch estimates the annual direct costs of common chronic conditions among adults continuously enrolled in Group Health Cooperative of Puget Sound (GHC) in 1992. GHC is a staffmodel HMO that provides health care services to approximately 400,000 persons in western Washington State. GHC is the country's largest consumer-governed health care organization; its 650 staff physicians provide health care services through twenty-eight primary care clinics, two specialty centers, and two hospitals. In addition, GHC has contractual relationships with external physicians and other health care professionals and facilities.
Cost allocation and resource intensity. The GHC information system captures diagnostic and procedural data on all ambulatory and inpatient episodes of care provided internally or by contracted providers. The information system also captures and fully allocates the delivery costs of all internal health care services as well as claims for covered services rendered by external providers. To allocate costs, a resource intensity weight is assigned to each service, procedure, pharmacy fill, or diagnostic test. The methodology for computing the resource intensity weight is unique to each cost center in the delivery system. For some service and cost centers, such as pharmacy, assigned costs are unweighted acquisition charges from suppliers. Costs that are not directly related to the delivery of services, such as insurance administration and marketing, are not allocated to enrollees and thus are not reported here. Any plan margin is included in this allocation, but because GHC is organized as a nonprofit consumer-governed cooperative, these revenues are redistributed into the delivery system.
Costs allocated to enrollees for services received from providers outside the GHC staff model are GHC's payments to those providers. Although such services will more likely reflect market prices than will services provided internally, they represent the financial liability that GHC incurs in delivering health care services to its enrollees: approximately half of inpatient admissions and half of all specialty visits (or 15 percent of all ambulatory encounters) during a typical year. Payments to non-GHC providers represent approximately 25 percent of total delivery system costs in a typical year.
Chronic conditions. We provide cost estimates for the following chronic conditions: anxiety, arthritis, back and neck pain, cancer, depression, diabetes, dementia, facial pain, gastrointestinal disease, headache, heart disease, human immunodeficiency virus (HIV) infection, hypertension, multiple sclerosis, panic disorder, pregnancy and pregnancy-related conditions, respiratory disease (asthma and chronic obstructive pulmonary disease [COPD]), and stroke. This list is not exhaustive but includes most of the important chronic conditions among adults. Pregnancy is included in this list because its duration qualifies it as a chronic condition (more than three months), and because it represents substantial health care services use and cost for women of childbearing age.
Persons with chronic conditions were identified from records of all inpatient and outpatient utilization for 1992. Diagnostic codes for ambulatory care received from GHC providers were obtained from treatment record forms completed by physicians or other providers for all primary and specialty care visits at the time of the encounter. GHC's automated data system captures up to two diagnoses per visit. A similar process was used for inpatient care, with the exception that up to ten International Classification of Diseases, Ninth Revision (ICD-9), codes were recorded for hospitalizations. A person was classified as having a chronic condition if the appropriate ICD-9 code appeared in any one of the diagnosis fields for all services received in 1992.
Persons with diabetes were identified by an algorithm designed by GHC's diabetes management program that uses ICD-9 codes and pharmacy and laboratory data to determine if a person is diabetic. 1 Persons with cancer were identified through the Surveillance, Epidemiology, and End Results (SEER) registry data provided by the Fred Hutchinson Cancer Research Center in Seattle. Because our cost estimates are based on annual prevalence during 1992, we included all persons who received any cancer diagnosis within the previous five years and any person who was on the diabetes registry in January 1993. We took advantage of existing registry data to define cancer and diabetes for this study and would have used similar data for other chronic conditions had they existed.
Comparability of the cost estimates. Although our estimates provide a good measure of the costs of chronic illness in managed care, they are specifically applicable only to the Seattle market. To compare these costs with those in other markets, we also estimated a measure of relative economic burden that is independent of dollars: the cost-elasticity of disease. The cost-elasticity, or responsiveness of costs with respect to disease, measures the percentage increase in costs that a health plan is likely to experience for a person with each chronic illness, holding age, sex, and other chronic conditions constant. Disease cost-elasticities are calculated from an ordinary least-squares regression that uses the (natural) logarithm of costs as the dependent variable and the person's age, sex, and chronic condition profile as independent variables.
2 Disease cost-elasticities are the exponent of the coefficients for each specific condition from this regression, adjusted for the variance around each coefficient.
Results
Sociodemographic data. GHC does not routinely collect sociodemographic data on its enrollees other than age and sex (Exhibit 1), but marketing surveys show that GHC enrolls a population that is similar to the community with respect to age, sex, and race but is slightly underrepresented at upper and lower income brackets. GHC enrollees have a slightly higher level of education than that of the general community. GHC's enrollees occasionally receive health care services outside the system that are not captured by information systems, but not to a degree that would bias cost estimates. GHC has an average annual enrollee turnover rate of about 15 percent, with a large, stable enrollment base. The turnover rate falls dramatically for enrollees who have been in GHC for two or more years.
Prevalence and costs. More than one-third of the study population (38 percent) had one or more chronic conditions in 1992, and 14 percent had two or more chronic conditions (Exhibit 1). Across all age groups, the population with at least one chronic condition had average costs at least twice those of the population with no chronic conditions (Exhibit 2). The population with two or more chronic conditions had costs at least three times those of the population with no chronic conditions. Persons with chronic conditions (38 percent of the population) accounted for 71 percent of the total costs. Sex-specific actual costs were age-adjusted; total costs were adjusted for the age and sex of the population with each chronic condition. We adjusted for age as a continuous variable after testing different formulations. We found that condition-specific estimates did not vary significantly based on how age was modeled. Costs for persons with more than one chronic condition contribute to the costs in each condition for which they have a diagnosis. Data in Exhibit 3 report the age-and sex-adjusted average costs of providing services to persons with specific chronic conditions. Cost-responsiveness estimates take into account a person's chronic condition profile (Exhibit 4). The coefficients from the ordinary least-squares regressions on which these estimates are based were all statistically significant, with the exception of those for the oldest male and female groups, primarily because of the relatively small numbers in these age groups. From the data reported in Exhibit 4, we would expect a person diagnosed with heart disease, for example, to cost 136 percent more than someone without such a diagnosis, after controlling for age, sex, and the set of chronic conditions included in this analysis. Interpretation of the responsiveness measures reported in Exhibit 4 must take into account the relative comparison group for a person diagnosed with a chronic condition. For example, the responsiveness measure for pregnancy (982 per- cent) is a large relative increment because young women are generally in good health yet experience high health care costs during their pregnancies. Conversely, a person diagnosed with dementia is only 175 percent more expensive than a comparable person without this diagnosis because the comorbidity and cost profile for a person who is likely to be diagnosed with dementia is high.
Distinguishing the relative cost effect of comorbidities is important with a chronically ill population. As reported in Exhibit 1, 14 percent of the adult GHC population was diagnosed with two or more chronic conditions during 1992. In some cases, the specific cost-responsiveness measures may not be as revealing because of the key role played by common comorbidities. For example, the marginal effect of diabetes may be muted by the frequent presence of heart disease and hypertension within this population. A diagnosis of diabetes alone would be expected to more than double costs after taking age, sex, and the set of chronic conditions into account. In contrast, diabetes along with hypertension would be expected to increase costs more than 303 percent (found by adding the responsiveness measures in Exhibit 4), and diabetes along with heart disease would be expected to increase costs by almost 311 percent.
Discussion
It is difficult to draw conclusions about relative resource use across chronic conditions from studies that use different method- ologies and data sets. Because we used data from a single large health plan, we are able to provide meaningful comparisons of the relative costs of treating people with a variety of chronic conditions. The greatest barrier to comparing our study with other cost-ofillness studies is that much of the published literature relies on national fee-for-service data or reimbursement schedules provided by large payers such as the Health Care Financing Administration or other public agencies. These cost estimates may not be relevant to the current managed care experience. Also, because these schedules are driven by a reimbursement process, they may not reflect the actual costs of health care services in any delivery system.
Another concern with drawing comparisons with previous studies is that most of the existing literature does not report cost estimates on a per capita basis or provide sufficient detail to allow per capita estimates to be constructed. One reason that per capita costs have not been reported is the inclusion of indirect costs, which often are based on aggregated data. For example, the family is the smallest unit of analysis in Kevin Weiss and colleagues' study of the cost of asthma.
3 Population-based data are essential if cost estimates for chronic and acute events are to be used to design and study the effective use of health care resources. One limitation of our study is that assessment of diagnostic status for the chronic conditions we studied, with the exceptions of cancer and diabetes, required use of services during 1992. One might argue that the cost differences we found are partly attributable to the selection of patients on the basis of use of services. We believe that the impact of this potential source of bias is relatively small. For example, Gregory Simon and colleagues reported that estimates of the relative direct costs of depressed versus nondepressed HMO enrollees were similar whether cases were identified by a visit or cases and controls were identified in a way that did not require a visit for depression. 4 Value of cost-effectiveness information. Efforts to control the amount and rate of growth of U.S. health care costs should focus on how care is organized and delivered to persons with chronic conditions. As our data suggest, a large share of total health care costs is attributable to caring for persons with chronic conditions. Improving care for such persons as financial constraints have become more acute requires using existing resources more efficiently.
All successful programs for managing chronic conditions must be guided by evidence of the cost-effectiveness of various clinical approaches. Understanding the way in which chronic conditions and comorbidities contribute to costs will guide clinicians and managers in the development and assessment of programs to reduce the cost and improve the health outcomes associated with chronic conditions. Cost should not be the only factor in deciding how to organize and deliver care, but the potential to improve outcomes on a population basis depends in part on delivering cost-effective services.
We did not control for relative disease severity within each condition because our goal is to provide a general measure of the resource use associated with common chronic conditions. Population-based disease management requires a global approach to planning clinical and financial commitments to specific groups of patients.
Fee-for-service versus managed care. There is no consensus about the comparability of the populations served by fee-for-service versus managed care providers. Selection issues related to the Medicare risk program have recently been studied at length, but no similar effort has been made for commercial markets since the industry shift to managed care quickened in the past decade. 5 Studies conducted prior to the recent growth in managed care argued that favorable selection may have existed for managed care providers, but this literature is outdated. 6 As the U.S. health care system shifts more toward managed care, the relevant research issue also will shift; the key question will be whether selection exists among various managed care plans, rather than between fee-for-service and managed care plans.
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